Rules and Regulations. Final rule; technical amendment

2,436 words·~11 min read·/register/2001/09/17/01-23043·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 3410-08-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 510, 520, 522, and 558 New Animal Drugs; Change of Sponsor; Technical Amendment AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; technical amendment. SUMMARY: The Food and Drug Administration

(FDA)is amending the animal drug regulations to reflect a change of sponsor for 43 approved new animal drug applications (NADAs) and 16 approved abbreviated new animal drug applications (ANADAs) from Hoechst Roussel Vet to Intervet, Inc. Technical amendments are also being made. This action is being taken to improve the accuracy of the agency’s regulations. DATES: This rule is effective September 17, 2001. FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209. SUPPLEMENTARY INFORMATION: Hoechst Roussel Vet, Perryville Corporate Park III, P.O. Box 4010, Clinton, NJ 08809-4010, has informed FDA that it has transferred ownership of, and all rights and interest in, the following NADAs and ANADAs to Intervet, Inc., P.O. Box 318, 405 State St., Millsboro, DE 19966. NADA Number Product Name 34-478 LASIX® Injection 34-621 LASIX® Tablets and Boluses 44-759 FLAVOMYCIN® Type A Medicated Article 45-188 LASIX® Packets 95-543 AMPROL HI-E®/FLAVOMYCIN® 95-547 AMPROL HI-E®/FLAVOMYCIN®/3-NITRO® 95-548 AMPROL®/3-NITRO®/FLAVOMYCIN® 95-549 AMPROL®/3-NITRO®/FLAVOMYCIN® 98-340 FLAVOMYCIN®/Monensin 98-341 FLAVOMYCIN®/3-NITRO®/COBAN® 101-628 FLAVOMYCIN®/3-NITRO®/ZOALENE® 101-629 FLAVOMYCIN®/ZOALENE® 102-380 LASIX® Syrup 104-494 PANACUR® 10% Suspension 111-278 PANACUR® Granules 22% 120-648 PANACUR®/SAFE-GUARD® Paste 121-473 PANACUR® Granules 22% 128-620 PANACUR®/SAFE-GUARD® 10% Suspension 130-185 FLAVOMYCIN®/Amprolium 130-661 FLAVOMYCIN®/CARB-O-SEP® 130-951 STENOROL® Type A Medicated Article 131-310 REGU-MATE® Solution 131-675 SAFE-GUARD® Type A Medicated Article 132-872 PANACUR®/SAFE-GUARD® 10% Paste 137-483 FLAVOMYCIN®/STENOROL® 137-600 SAFE-GUARD® Type A Medicated Article 138-612 FINAPLIX®-S; FINAPLIX®-H Implants 139-189 SAFE-GUARD® ENPROAL Feedblocks 139-473 STENOROL®/STAFAC® 140-339 FLAVOMYCIN®/NICARB® 140-340 STENOROL®/LINCOMIX® 140-533 STENOROL®/3-NITRO®/BMD® 140-584 STENOROL®/BMD® 140-824 STENOROL® Type A Medicated Article 140-843 MONTEBAN®/FLAVOMYCIN®/3-NITRO® 140-845 FLAVOMYCIN®/MONTEBAN® 140-897 REVALOR®-S; REVALOR®-G Implants 140-918 STENOROL®/FLAVOMYCIN® 140-919 STENOROL®/BMD® 140-954 SAFE-GUARD® Type A/LINCOMIX® 140-992 REVALOR®-200; REVALOR®-H Implants 141-034 GAINPRO® Type A Medicated Article 141-129 AVATEC®/FLAVOMYCIN® 200-075 SACOX® Type A Medicated Article 200-080 SACOX®/3-NITRO®/FLAVOMYCIN® 200-081 SACOX®/3-NITRO®/BMD® 200-082 SACOX®/BMD® 200-083 SACOX®/FLAVOMYCIN® 200-086 SACOX®/ALBAC®/3-NITRO® 200-089 SACOX®/BACIFERM® 200-090 SACOX®/LINCOMIX®/3-NITRO® 200-091 SACOX®/3-NITRO®/AUREOMYCIN® 200-092 SACOX®/STAFAC® 200-093 SACOX®/LINCOMIX® 200-094 SACOX®/STAFAC®/3-NITRO® 200-095 SACOX®/AUREOMYCIN® 200-096 SACOX®/TERRAMYCIN® 200-097 SACOX®/3-NITRO® 200-143 SACOX®/3-NITRO®/BACIFERM® Accordingly, the agency is amending the regulations in 21 CFR 520.48, 520.905a, 520.905b, 520.905c, 520.905d, 520.905e, 520.1010a, 520.1010b, 520.1010c, 522.1010, 522.2476, 522.2477, 558.55, 558.58, 558.95, 558.198, 558.258, 558.265, 558.355, 558.363, 558.366, and 558.550 to reflect the transfers of ownership. In addition, the sections in 21 CFR parts 520 and 522 are being revised to reflect current format. Following the change of sponsor of these NADAs, Hoechst Roussel Vet is no longer the sponsor of any approved applications. Therefore, 21 CFR 510.600(c) is amended to remove the entries for this sponsor. This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. List of Subjects 21 CFR Part 510 Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements. 21 CFR Parts 520 and 522 Animal drugs. 21 CFR Part 558 Animal drugs, Animal feeds. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS 1. The authority citation for 21 CFR part 510 continues to read as follows: Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. § 510.600 [Amended] 2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for “Hoechst Roussel Vet” and in the table in paragraph (c)(2) by removing the entry for “012799”. PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS 3. The authority citation for 21 CFR part 520 continues to read as follows: Authority: 21 U.S.C. 360b. 4. Section 520.48 is revised to read as follows: § 520.48 Altrenogest solution.

(a)*Specifications* . Each milliliter

(mL)of solution contains 2.2 milligrams

(mg)altrenogest.

(b)*Sponsor* . See No. 057926 in § 510.600(c) of this chapter.

(c)*Special considerations* . Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)*Conditions of use* —(1) *Amount* . 1.0 mL per 110 pounds body weight (0.044 mg per kilogram) daily for 15 consecutive days.

(2)*Indications for use* . For suppression of estrus in mares.

(3)*Limitations* . For oral use in horses only; avoid contact with the skin. Do not administer to horses intended for use as food. § 520.905a [Amended] 5. Section 520.905a *Fenbendazole suspension* is amended in paragraph

(b)by removing “012799” and by adding in its place “057926”. § 520.905b [Amended] 6. Section 520.905b *Fenbendazole granules* is amended in paragraph

(b)by removing “012799” and by adding in its place “057926”. § 520.905c [Amended] 7. Section 520.905c *Fenbendazole paste* is amended in paragraph

(b)by removing “012799” and by adding in its place “057926”. § 520.905d [Amended] 8. Section 520.905d *Fenbendazole powder* is amended in paragraph

(b)by removing “012799” and by adding in its place “057926”. § 520.905e [Amended] 9. Section 520.905e *Fenbendazole blocks* is amended in paragraph

(b)by removing “012799” and by adding in its place “057926”. 10. Section 520.1010 is revised to read as follows: § 520.1010 Furosemide.

(a)*Specifications* .

(1)Each tablet contains 12.5 or 50 milligrams

(mg)furosemide.

(2)Each bolus contains 2 grams

(g)furosemide.

(3)Each packet of powder contains 2 g furosemide.

(4)Each milliliter of syrup contains 10 mg furosemide.

(b)*Sponsors* . See sponsor numbers in § 510.600(c) of this chapter for use of dosage forms and strengths listed in paragraph

(a)of this section for uses as in paragraph

(d)of this section.

(1)No. 000010 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section.

(2)No. 000093 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(B) of this section.

(3)No. 057926 for tablets in paragraph (a)(1) of this section for conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of this section; for boluses in paragraph (a)(2) of this section and powder in paragraph (a)(3) of this section for conditions of use in paragraph (d)(1) of this section; and for syrup in paragraph (a)(4) of this section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(A).

(c)*Special considerations* . Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)*Conditions of use* . It is used as follows:

(1)*Cattle* —(i) *Amount* . 1 to 2 mg per pound (/lb) body weight using powder, or one 2-g bolus per animal, per day.

(ii)*Indications for use* . For treatment of physiological parturient edema of the mammary gland and associated structures.

(iii)*Limitations* . Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.

(2)*Dogs* —(i) *Amount* . 1 to 2 mg/lb body weight, once or twice daily.

(ii)*Indications for use* —(A) For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(B)For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency.

(3)*Cats* —(i) *Amount* . 1 to 2 mg/lb body weight, once or twice daily.

(ii)*Indications for use* . For treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema. § 520.1010a [Removed] 11. Section 520.1010a *Furosemide tablets or boluses* is removed. § 520.1010b [Removed] 12. Section 520.1010b *Furosemide powder* is removed. § 520.1010c [Removed] 13. Section 520.1010c *Furosemide syrup* is removed. PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS 14. The authority citation for 21 CFR part 522 continues to read as follows: Authority: 21 U.S.C. 360b. 15. Section 522.1010 is revised to read as follows: § 522.1010 Furosemide.

(a)*Specifications* . Each milliliter of solution contains 50 milligrams

(mg)of furosemide diethanolamine.

(b)*Sponsors* . See sponsors in § 510.600(c) of this chapter for use as in paragraph

(d)of this section.

(1)No. 000010 for use as in paragraphs (d)(1) and (d)(2)(ii) of this section.

(2)No. 000864 for use as in paragraph (d)(2)(ii) of this section.

(3)No. 057926 for use as in paragraphs (d)(1), (d)(2)(i), and (d)(3) of this section.

(c)*Special considerations* . Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)*Conditions of use* —(1) *Dogs and cats* —(i) Amount. 1.25 to 2.5 mg per pound (/lb) body weight once or twice daily, intramuscularly or intravenously.

(ii)*Indications for use* . For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema.

(2)*Horses* —(i) *Amount* . 250 to 500 mg per animal once or twice daily, intramuscularly or intravenously.

(A)*Indications for use* . For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency, and acute noninflammatory tissue edema.

(B)*Limitations* . Do not use in horses intended for food.

(ii)*Amount* . 0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously.

(A)*Indications for use* . For treatment of acute noninflammatory tissue edema.

(B)*Limitations* . Do not use in horses intended for food.

(3)*Cattle* —(i) *Amount* . 500 mg/animal once daily, intramuscularly or intravenously; or 250 mg/animal twice daily at 12-hour intervals, intramuscularly or intravenously.

(ii)*Indications for use* . For the treatment of physiological parturient edema of the mammary gland and associated structures.

(iii)*Limitations* . Treatment not to exceed 48 hours post-parturition. Milk taken during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment. 16. Section 522.2476 is revised to read as follows: § 522.2476 Trenbolone acetate.

(a)[Reserved]

(b)*Sponsors* . See sponsors in § 510.600(c) of this chapter for use as in paragraph

(d)of this section.

(1)No. 021641 for use as in paragraphs (d)(1) and (d)(2) of this section.

(2)No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), (d)(2)(ii), and (d)(2)(iii) of this section.

(c)*Related tolerances* . See § 556.739 of this chapter.

(d)*Conditions of use* —(1) *Steers fed in confinement for slaughter* —(i) *Amount* . Use 126 days prior to slaughter; should be reimplanted once after 63 days.

(A)140 milligrams

(mg)trenbolone acetate (one implant consisting of 7 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B)140 mg trenbolone acetate (one implant consisting of 8 pellets, each of 7 pellets containing 20 milligrams trenbolone acetate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(ii)*Indications for use* . For improved feed efficiency.

(iii)*Limitations* . Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals.

(2)*Heifers fed in confinement for slaughter* —(i) Amount. Use last 63 days prior to slaughter.

(A)200 mg trenbolone acetate (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B)200 mg of trenbolone acetate (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg of trenbolone acetate, and 1 pellet containing 29 mg of tylosin tartrate) per implant dose.

(ii)*Indications for use* . For increased rate of weight gain and improved feed efficiency.

(iii)*Limitations* . Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. 17. Section 522.2477 is amended by revising paragraph

(b)to read as follows: § 522.2477 Trenbolone acetate and estradiol.

(b)*Sponsors* . See sponsors in § 510.600(c) of this chapter for uses as in paragraph

(d)of this section.

(1)No. 021641 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B), (d)(1)(ii), (d)(1)(iii), and (d)(3) of this section.

(2)No. 057926 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(C), (d)(1)(i)(D), (d)(1)(ii), (d)(1)(iii), (d)(2), (d)(3)(i)(A), (d)(3)(ii), and (d)(3)(iii) of this section. PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS 18. The authority citation for 21 CFR part 558 continues to read as follows: Authority: 21 U.S.C. 360b, 371. § 558.55 [Amended] 19. Section 558.55 *Amprolium* is amended in the table in paragraphs (d)(2)(iii) by removing “012799” wherever it appears under the “Limitations” and “Sponsor” columns and by adding in its place “057926”. § 558.58 [Amended] 20. Section 558.58 *Amprolium and ethopabate* is amended in the table in paragraphs (d)(1)(ii) and (d)(1)(iii) by removing “012799” wherever it appears in the “Limitations” column and by adding in its place “057926”. § 558.95 [Amended] 21. Section 558.95 *Bambermycins* is amended in paragraphs (a)(1), (a)(2), (a)(5), (d)(1)(vi)( *b* ), and (d)(1)(vii)( *b* ) by removing “012799” and by adding in its place “057926”; and in paragraphs (d)(1)(xi)( *b* ), and (d)(1)(xii)( *b* ) by removing “012799 and 046573” and by adding in its place “046573 and 057926”. § 558.198 [Amended] 22. Section 558.198 *Diclazuril* is amended in the table in paragraphs (d)(1)(iii) by removing “012799” under the “Limitations” column and by adding in its place “057926.” § 558.258 [Amended] 23. Section 558.258 *Fenbendazole* is amended in paragraph

(a)by removing “012799” and by adding in its place “057926”. § 558.265 [Amended] 24. Section 558.265 *Halofuginone hydrobromide* is amended in paragraph

(a)by removing “012799” and by adding in its place “057926”. § 558.355 [Amended] 25. Section 558.355 *Monensin* is amended in paragraphs (b)(10), (f)(2)(v)( *b* ), and (f)(2)(vi)( *b* ) by removing “012799” and by adding in its place “057926”. § 558.363 [Amended] 26. Section 558.363 *Narasin* is amended in paragraphs (a)(4), (a)(5), (d)(1)(vii)(B), and (d)(1)(xii)(B) by removing “012799” and by adding in its place “057926”. § 558.366 [Amended] 27. Section 558.366 *Nicarbazin* is amended in the table in paragraph

(c)in the entry for “Bambermycins 1 to 2” under the “Sponsor” column by removing “012799” and by adding in its place “057926”. § 558.550 [Amended] 28. Section 558.550 *Salinomycin* is amended in paragraph (a)(2) by removing “012799” and by adding in its place “057926”; and in paragraphs (d)(1)(xv)( *c* ) and (d)(1)(xvi)( *c* ) by removing “012799 and 046573” and by adding in its place “046573 and 057926”. Dated: August 31, 2001. Claire M. Lathers, Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. [FR Doc. 01-23043 Filed 9-14-01; 8:45 am]

Connectionstraces to 5

Traces to 5 documents

CFR

U.S. Code

5 references not yet in our index